Top Page
Bodycote
(LSE:BOY)
Bodycote (BOY) vs. iShares MSCI United Kingdom ETF (EWC)
Bodycote Business Overview & Revenue Model
Bodycote Financial Statement Overview
| Breakdown | ||||
| Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|
| Income Statement | Total Revenue | |||
| 757.10M | 802.50M | 743.60M | 615.80M | 598.00M | Gross Profit |
| 109.30M | 108.10M | 269.70M | 225.70M | 186.90M | EBIT |
| 37.90M | 119.20M | 94.90M | 80.20M | 57.70M | EBITDA |
| 124.00M | 201.70M | 186.60M | 167.70M | 97.00M | Net Income Common Stockholders |
| 20.00M | 85.60M | 73.70M | 59.50M | 400.00K |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | |||
| 19.10M | 45.20M | 37.20M | 39.30M | 30.70M | Total Assets |
| 1.07B | 1.14B | 1.17B | 1.07B | 1.11B | Total Debt |
| 150.90M | 96.90M | 136.60M | 156.20M | 128.80M | Net Debt |
| 131.80M | 51.70M | 99.40M | 116.90M | 98.10M | Total Liabilities |
| 397.50M | 344.40M | 385.70M | 384.40M | 428.60M | Stockholders Equity |
| 668.10M | 790.80M | 780.90M | 684.70M | 680.50M |
| Cash Flow | Free Cash Flow | |||
| 82.50M | 109.20M | 70.10M | 87.10M | 74.50M | Operating Cash Flow |
| 152.60M | 191.60M | 137.10M | 139.10M | 134.40M | Investing Cash Flow |
| -112.80M | -71.20M | -62.30M | -104.80M | -124.70M | Financing Cash Flow |
| -67.60M | -110.20M | -76.60M | -24.80M | -1.30M |
Bodycote Technical Analysis
Bodycote Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | £5.08B | 21.20 | 23.50% | 1.53% | 0.64% | 4.92% | |
75 Outperform | £6.41B | 20.55 | 17.83% | 1.78% | -4.95% | 36.95% | |
74 Outperform | £591.76M | 30.34 | 16.39% | 1.69% | 3.13% | 24.54% | |
74 Outperform | £610.99M | 12.36 | 14.06% | 6.22% | -1.26% | 6.56% | |
72 Outperform | £990.01M | 52.23 | 2.74% | 5.73% | -5.66% | -76.42% | |
72 Outperform | £4.41B | 23.11 | 16.16% | 3.92% | -1.03% | 4.06% | |
66 Neutral | $4.51B | 12.29 | 5.40% | 3.67% | 4.15% | -12.21% |
Bodycote Corporate Events
Bodycote plc announced the continuation of its share buyback program, purchasing 29,362 ordinary shares as part of its extended program. This move is part of a broader strategy to enhance shareholder value, having repurchased a total of 13,512,523 shares since March 2024, indicating a strong commitment to returning capital to shareholders and potentially improving market confidence.
The most recent analyst rating on (GB:BOY) stock is a Buy with a £955.00 price target. To see the full list of analyst forecasts on Bodycote stock, see the GB:BOY Stock Forecast page.
Bodycote PLC has announced a change in its major holdings, with Martin Currie Investment Management Limited adjusting its voting rights in the company. The adjustment sees Martin Currie’s voting rights decrease from 5.27% to 4.96%, indicating a slight reduction in their stake. This change could potentially impact Bodycote’s shareholder dynamics and influence future decision-making processes within the company.
The most recent analyst rating on (GB:BOY) stock is a Buy with a £890.00 price target. To see the full list of analyst forecasts on Bodycote stock, see the GB:BOY Stock Forecast page.
Bodycote’s recent trading update reveals a 6% decline in group revenue for the first four months of 2025 compared to the previous year, attributed to strong prior year comparators and reduced energy surcharges. Despite challenges in the Automotive and Industrial markets, the company has seen improvements in Civil Aerospace and Defence sectors. Bodycote is advancing its ‘Optimise, Perform & Grow’ strategy, aiming to enhance operational efficiency and resilience, with plans to expand its plant and overhead reduction program. The company anticipates a second-half weighted improvement in adjusted operating profit, driven by new contracts in Defence and Oil & Gas, as well as growth in Aerospace & Defence.
The most recent analyst rating on (GB:BOY) stock is a Buy with a £955.00 price target. To see the full list of analyst forecasts on Bodycote stock, see the GB:BOY Stock Forecast page.
Bodycote plc announced that all resolutions proposed at its Annual General Meeting on May 21, 2025, were approved by shareholders. The resolutions included the re-election of board members, approval of the directors’ remuneration policy, and the renewal of authorities related to share capital management. The successful passage of these resolutions reflects shareholder confidence in the company’s governance and strategic direction, potentially strengthening Bodycote’s market position and operational stability.
The most recent analyst rating on (GB:BOY) stock is a Buy with a £955.00 price target. To see the full list of analyst forecasts on Bodycote stock, see the GB:BOY Stock Forecast page.
Bodycote plc has announced the appointment of Emmanuelle Dubu as a Non-Executive Director, effective June 23, 2025. Dubu, with extensive experience in international engineering and leadership roles, will join the Remuneration, Nomination, and Audit committees. Her background in metallurgy and international industry experience is expected to contribute significantly to Bodycote’s board. Additionally, Lili Chahbazi has been appointed as the Senior Independent Director, succeeding Patrick Larmon, who will step down from the board in September 2025. These changes reflect Bodycote’s strategic focus on strengthening its leadership team to enhance its market position and stakeholder engagement.
The most recent analyst rating on (GB:BOY) stock is a Buy with a £955.00 price target. To see the full list of analyst forecasts on Bodycote stock, see the GB:BOY Stock Forecast page.
Bodycote plc has announced the continuation of its share buyback programme, purchasing 1,397 ordinary shares at an average price of 533.515 pence per share. This move is part of an extended programme that has seen the company buy back a total of 12,712,626 shares, aiming to cancel these shares and reduce the number of shares in circulation, which could potentially enhance shareholder value by increasing earnings per share.
The most recent analyst rating on (GB:BOY) stock is a Buy with a £955.00 price target. To see the full list of analyst forecasts on Bodycote stock, see the GB:BOY Stock Forecast page.
Bodycote plc has announced the purchase and cancellation of 122,951 ordinary shares as part of its ongoing share buyback programme. This move is part of an extended programme that has seen the company buy back a total of 12,602,072 shares, aiming to optimize its capital structure and potentially enhance shareholder value.
Bodycote plc announced the continuation of its share buyback programme, purchasing 37,485 ordinary shares at an average price of 482.8736 pence per share. This move is part of an extended programme aimed at reducing the number of shares in circulation, thereby potentially increasing the value of remaining shares and enhancing shareholder value. Following this transaction, Bodycote has a total of 179,142,288 ordinary shares in issue, with no shares held in treasury. This strategic financial maneuver is expected to strengthen Bodycote’s market position and demonstrate its commitment to returning value to shareholders.
Bodycote plc has announced the purchase and cancellation of 177,715 of its ordinary shares as part of its extended share buyback programme. This move is part of a broader strategy to manage the company’s capital structure, having acquired a total of 12,276,399 shares since March 2024, which may impact shareholder value and market perception.
Bodycote PLC announced that its Chief Financial Officer, Ben Fidler, has exercised shares under the Bodycote Incentive Plan. A total of 63,906 shares were exercised, with 29,835 shares sold to cover tax liabilities and 34,071 shares retained. This transaction reflects the company’s ongoing commitment to aligning executive interests with shareholder value, potentially impacting its market positioning and stakeholder confidence.
Bodycote PLC announced that its CEO, Jim Fairbairn, exercised shares from the Bodycote Incentive Plan granted in 2024. The transaction involved exercising 94,139 shares, with 43,949 sold to cover tax liabilities and 50,190 retained, highlighting a strategic financial decision by the company’s leadership.
Bodycote plc has announced the performance targets for its Bodycote Incentive Plan (BIP) for 2025, following the release of its 2024 Annual Report. The targets include metrics for Return on Capital Employed, Earnings Per Share growth, and CO2 emissions reduction, reflecting the company’s commitment to financial performance and sustainability goals. These measures are expected to align with Bodycote’s strategic objectives and enhance its market position, potentially impacting shareholder value and environmental performance.
Bodycote plc has released its 2024 Annual Report and Accounts along with the notice for the 2025 Annual General Meeting. These documents are available for inspection on the National Storage Mechanism and the company’s website. The announcement underscores Bodycote’s commitment to transparency and regulatory compliance, potentially impacting investor confidence and stakeholder engagement.
Bodycote plc has announced the purchase of 43,776 of its own ordinary shares as part of its extended share buyback programme, with the intention to cancel these shares. This move is part of a broader strategy to manage the company’s capital structure and enhance shareholder value, reflecting confidence in its financial position and future prospects.
Bodycote plc has announced a continuation of its share buyback programme, purchasing 43,525 of its ordinary shares at prices ranging from 455.4p to 482.2p per share. This move is part of an extended programme that began in December 2024, with the company having bought a total of 11,796,983 shares since March 2024. The purchased shares will be canceled, reducing the total number of shares in issue to 179,659,189, which could potentially enhance shareholder value by increasing earnings per share.
Bodycote plc has announced the purchase of 44,761 of its ordinary shares as part of its extended share buyback program. This move, which is part of a larger strategy that has seen the company repurchase over 11 million shares since March 2024, aims to reduce the number of shares in circulation, potentially enhancing shareholder value and reflecting confidence in the company’s financial health.
Bodycote PLC has announced a change in the breakdown of its voting rights, with The Goldman Sachs Group, Inc. now holding an 8.001455% stake in the company. This adjustment in voting rights, as reported on April 4, 2025, reflects a slight increase from the previous position and may influence the company’s strategic decisions and stakeholder dynamics.
Bodycote plc has announced the continuation of its share buyback program, purchasing 40,000 ordinary shares at prices ranging from 481.4p to 520.5p per share. This move is part of an extended program initiated in December 2024, aiming to enhance shareholder value by reducing the number of shares in circulation, thereby increasing the value of remaining shares. The company has purchased a total of 11,576,307 shares since March 2024, reflecting its commitment to returning capital to shareholders.
Bodycote plc has announced the continuation of its share buyback program, purchasing 32,419 ordinary shares at an average price of 560.4150 pence per share. This move is part of an extended program initiated in December 2024, with the company having bought a total of 11,466,307 ordinary shares since March 2024. The cancellation of these shares will reduce the total number of shares in issue to 179,989,865, potentially increasing shareholder value and consolidating the company’s market position.
Bodycote plc has announced the purchase of 35,000 of its ordinary shares as part of its extended share buyback programme, with plans to cancel these shares. This move is part of a broader strategy to manage its capital structure, having repurchased a total of 11,433,888 shares since March 2024, reflecting the company’s commitment to enhancing shareholder value.
Bodycote plc has announced the continuation of its share buyback program, purchasing 32,358 ordinary shares at a volume-weighted average price of 572.3309 pence per share. This move is part of the extended program initiated in December 2024, and the company intends to cancel these shares, reducing the total number of shares in issue to 180,107,323. This strategic action reflects Bodycote’s commitment to optimizing its capital structure and potentially enhancing shareholder value.
Bodycote plc has announced the continuation of its share buyback program, purchasing 25,711 ordinary shares through HSBC Bank PLC as part of an extended initiative. This strategic move, which involves canceling the acquired shares, aims to optimize the company’s capital structure and potentially enhance shareholder value by reducing the number of shares in circulation.
Bodycote plc has announced the continuation of its share buyback program, purchasing 21,402 of its ordinary shares at an average price of 567.7881 pence per share. This move is part of an extended program that began in December 2024, with the company having acquired a total of 11,290,780 shares since March 2024. The cancellation of these shares will reduce the total number of shares in issue, potentially increasing the value of remaining shares and demonstrating the company’s commitment to returning value to shareholders.
Bodycote plc has announced the continuation of its share buyback program, purchasing 30,588 ordinary shares at prices ranging from 557.0p to 571.0p per share. This move is part of an extended program that began in December 2024, with the company having acquired a total of 11,269,378 shares since March 2024. The cancellation of these shares will reduce the total number of shares in issue, potentially increasing the value for remaining shareholders.
Bodycote PLC, a UK-based company, has experienced a change in the voting rights distribution as reported by The Goldman Sachs Group, Inc. The notification indicates that Goldman Sachs now holds a total of 8.000080% of voting rights in Bodycote, up from a previous position of 7.158152%. This change signifies a notable increase in Goldman Sachs’ influence within the company, potentially impacting Bodycote’s strategic decisions and stakeholder dynamics.
Bodycote plc has announced the continuation of its share buyback program, purchasing 43,875 of its ordinary shares through HSBC Bank PLC. This move is part of an extended program that has seen the company buy back a total of 11,024,355 shares since March 2024. The company intends to cancel the purchased shares, which will affect the total number of voting rights, now standing at 180,431,817 shares. This strategic financial maneuver is aimed at optimizing the company’s capital structure and potentially enhancing shareholder value.
Bodycote plc has announced the purchase of 63,017 of its ordinary shares as part of an extended share buyback programme, with the intention to cancel these shares. This move is part of a larger strategy, having bought a total of 10,915,782 shares since March 2024, aimed at optimizing the company’s capital structure and potentially enhancing shareholder value.